To test the hypothesis that nimodipine improves functional outcome in acute ischemic hemispheric stroke.
- Nimodipine (Nimotop®)Drug
Intervention Desc: Calcium channel blocker (L-type calcium channels)
Randomized, double-blind, multicenter, placebo-controlled trial of 350 patients.
Patients were randomized to receive nimodipine 120 mg/d PO or matching placebo for 21 days. All patients received neurological examinations on admission, days 1, 7 and 21, and at 3 and 12 months.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Rankin grade, neurological score, and mobility at 12 months.|
|Secondary||Survival and domicile at 12 months.|